42 studies found for:    " September 14, 2011":" October 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Not yet recruiting A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
2 Terminated
Has Results
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
3 Active, not recruiting A Commitment Device for Medication Adherence Among HIV Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV
Intervention: Other: Medication Adherence among HIV/AIDS Patients
4 Active, not recruiting Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Cobicistat;   Drug: Darunavir
5 Unknown  Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Condition: HIV
Intervention: Biological: Sci-B-Vac
6 Completed Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: Tenofovir;   Drug: Efavirenz
7 Unknown  Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
Conditions: HIV Infection;   Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
8 Terminated A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Condition: HIV Infection
Interventions: Biological: HIV-1 Tat/delta-V2 Env combined vaccine;   Biological: HIV-1 delta-V2 Env vaccine;   Biological: HIV-1 Tat vaccine
9 Recruiting RAltegravir Switch STudy: Effects on Endothelial Recovery
Conditions: HIV Infection;   Endothelial Dysfunction
Intervention: Drug: raltegravir
10 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
11 Recruiting Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section
Condition: Human Immunodeficiency Virus
Intervention:
12 Unknown  Dimiracetam in Painful Neuropathies Affecting AIDS Patients
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: Dimiracetam;   Drug: Dimiracetam 25 mg
13 Recruiting Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months
Conditions: HIV-1 Infection;   Cardiovascular Disease
Interventions: Other: Control;   Other: Intervention Group
14 Unknown  The Effect of Probiotics in HIV-1 Infection
Condition: HIV-1 Infection
Interventions: Dietary Supplement: Multi-strain probiotic;   Dietary Supplement: Placebo;   Other: Control
15 Recruiting Renal Transplantation and Raltegravir in HIV-Infected Patients
Conditions: HIV-1 Infection;   Chronic Renal Insufficiency
Intervention: Drug: Raltegravir
16 Completed Etravirine Plus 2 Analogs in HIV-infected Patients
Condition: HIV-1-infection
Intervention:
17 Active, not recruiting
Has Results
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
18 Unknown  Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Conditions: Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:
19 Recruiting Safer Sex Program for Young African-American Men
Conditions: Gonorrhea;   Chlamydia;   Trichomoniasis;   Syphilis;   HIV Infections
Intervention: Behavioral: Intervention
20 Active, not recruiting Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VSV-Indiana HIV gag vaccine;   Biological: Placebo injection (normal saline)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years